Issue Brief

Testimony before the Committee on Energy on Commerce, Subcommittee on Oversight and Investigations, United States House of Representatives

Alan Coukell, Director, Medical Safety Portfolio, Pew Health Group - April 13 2011

"Chairman Stearns, Ranking Member DeGette, and members of the Oversight and Investigations Subcommittee, thank you for the opportunity to submit testimony about the essential steps Congress must take to protect Americans and ensure the integrity of our drug supply."

"A major focus of the Pew Health Group is identifying ways to address risks to the U.S. pharmaceutical supply chain. Last month, we hosted a two-day conference that included representatives of brand and generic pharmaceutical manufacturers, active ingredient makers, federal and state regulators, major and secondary pharmaceutical wholesalers, chain and independent pharmacies, consumer and health professional organizations and independent supply chain experts. The convening was structured around a discussion draft of a white paper entitled “After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs,” which was shared with conference participants in advance."

Download the PDF to read the complete testimony from Alan Coukell.

Media Contact: Linda Paris

Topics: Drug Safety, Health

Project: Drug Safety Project

Media Contact

Tami Holzman

Officer, Communications